| Year |
Citation |
Score |
| 2024 |
Bos S, Murray J, Marchetti M, Cheng GS, Bergeron A, Wolff D, Sander C, Sharma A, Badawy SM, Peric Z, Piekarska A, Pidala J, Raj K, Penack O, Kulkarni S, et al. ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft--host disease in adults. The European Respiratory Journal. PMID 38485149 DOI: 10.1183/13993003.01727-2023 |
0.323 |
|
| 2024 |
Baumrin E, Shin DB, Mitra N, Pidala J, El Jurdi N, Lee SJ, Loren AW, Gelfand JM. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease. Jama Dermatology. PMID 38416506 DOI: 10.1001/jamadermatol.2023.6277 |
0.366 |
|
| 2024 |
Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, Roth JA, Wright W, Steuten LMG, Pidala JA, Mishra A, Maziarz RT, Westervelt P, McGuirk JP, Cutler C, et al. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. Jco Oncology Practice. OP2300413. PMID 38261970 DOI: 10.1200/OP.23.00413 |
0.336 |
|
| 2024 |
Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K, North B, Kim J, Teer JK, Yao J, Yoder SJ, Nishihori T, Bejanyan N, Pidala J, Elmariah H. Association between , and genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics. PMID 38189154 DOI: 10.2217/pgs-2023-0204 |
0.431 |
|
| 2023 |
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, ... ... Pidala J, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Transplantation and Cellular Therapy. PMID 37952648 DOI: 10.1016/j.jtct.2023.11.010 |
0.475 |
|
| 2023 |
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, Bhatt N, Bhatt VR, DeFilipp Z, Diaz MA, Farhadfar N, et al. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplantation and Cellular Therapy. PMID 37844687 DOI: 10.1016/j.jtct.2023.10.010 |
0.45 |
|
| 2023 |
Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, et al. A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry. Transplantation and Cellular Therapy. PMID 37517612 DOI: 10.1016/j.jtct.2023.07.021 |
0.445 |
|
| 2023 |
Im A, Pusic I, Onstad L, Kitko CL, Hamilton BK, Alousi AM, Flowers ME, Sarantopoulos S, Carpenter P, White J, Arai S, El Jurdi N, Chen G, Cutler C, Lee S, ... Pidala J, et al. Patient-reported treatment response in chronic graft--host disease. Haematologica. PMID 37226713 DOI: 10.3324/haematol.2023.282734 |
0.322 |
|
| 2023 |
Rashid N, Arora M, Jurdi NE, Onstad L, Pidala JA, Flowers ME, Lee SJ. Frailty in Patients with Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. PMID 36921916 DOI: 10.1016/j.jtct.2023.03.010 |
0.455 |
|
| 2022 |
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, ... ... Pidala JA, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial. Transplantation and Cellular Therapy. PMID 36584941 DOI: 10.1016/j.jtct.2022.12.017 |
0.461 |
|
| 2022 |
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, et al. Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy. PMID 35863740 DOI: 10.1016/j.jtct.2022.07.014 |
0.436 |
|
| 2022 |
Saliba RM, Majid AA, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, et al. Characteristics of Graft-versus-Host Disease (GvHD) after Post-transplant Cyclophosphamide versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy. PMID 35853610 DOI: 10.1016/j.jtct.2022.07.013 |
0.477 |
|
| 2022 |
Cuvelier GDE, Schoettler M, Buxbaum NP, Pinal-Fernandez I, Schmalzing M, Distler JHW, Penack O, Santomasso BD, Zeiser R, Angstwurm K, MacDonald KPA, Kimberly WT, Taylor N, Bilic E, Banas B, ... ... Pidala J, et al. Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplantation and Cellular Therapy. PMID 35662591 DOI: 10.1016/j.jtct.2022.05.038 |
0.331 |
|
| 2022 |
Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, Cutler C, Hamilton BK, Lee SJ, Arora M. Durable discontinuation of systemic therapy in patients affected by chronic graft versus host disease. Haematologica. PMID 35615925 DOI: 10.3324/haematol.2021.279814 |
0.42 |
|
| 2022 |
Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, ... ... Pidala J, et al. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. PMID 35017119 DOI: 10.1016/j.jtct.2022.01.003 |
0.421 |
|
| 2021 |
Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Malki MMA, et al. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. Transplantation and Cellular Therapy. PMID 34844022 DOI: 10.1016/j.jtct.2021.11.012 |
0.412 |
|
| 2021 |
Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, ... ... Pidala J, et al. Phase 2 multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-vs-host disease. Blood Advances. PMID 34649279 DOI: 10.1182/bloodadvances.2021005552 |
0.315 |
|
| 2021 |
Bhatt VR, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MMA, Badawy SM, Beitinjaneh A, Ganguly S, Hamilton B, Hildebrandt GC, Lekakis LJ, Liu H, Maziarz RT, et al. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. Transplantation and Cellular Therapy. PMID 34637965 DOI: 10.1016/j.jtct.2021.10.002 |
0.431 |
|
| 2021 |
Jayani RV, Pidala J, Jim H, Whiting J, Mo Q, Mishra A. Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes. Clinical Hematology International. 3: 34-39. PMID 34595465 DOI: 10.2991/chi.k.210221.001 |
0.36 |
|
| 2021 |
DeFilipp Z, Alousi A, Pidala J, Carpenter PA, Onstad L, Arai S, Arora M, Cutler CS, Flowers ME, Kitko CL, Chen GL, Lee SJ, Hamilton BK. Non-relapse mortality among patients diagnosed with chronic GVHD: An updated analysis from The Chronic GVHD Consortium. Blood Advances. PMID 34521116 DOI: 10.1182/bloodadvances.2021004941 |
0.39 |
|
| 2021 |
Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, Jaglowski S, Pidala J, Cutler C. Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplantation and Cellular Therapy. PMID 34481113 DOI: 10.1016/j.jtct.2021.08.017 |
0.374 |
|
| 2021 |
Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation. PMID 34381169 DOI: 10.1038/s41409-021-01428-1 |
0.395 |
|
| 2021 |
Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, ... ... Pidala J, et al. Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation. Transplantation and Cellular Therapy. PMID 34329754 DOI: 10.1016/j.jtct.2021.07.023 |
0.438 |
|
| 2021 |
Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, ... Pidala J, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. British Journal of Haematology. PMID 34254289 DOI: 10.1111/bjh.17700 |
0.34 |
|
| 2021 |
Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, et al. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Advances. 5: 2740-2750. PMID 34242388 DOI: 10.1182/bloodadvances.2021004225 |
0.316 |
|
| 2021 |
Inamoto Y, Martin PJ, Onstad LE, Cheng GS, Williams KM, Pusic I, Ho VT, Arora M, Pidala J, Flowers MED, Gooley TA, Lawler RL, Hansen JA, Lee SJ. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: Plasma MMP-9 in BOS. Transplantation and Cellular Therapy. PMID 34126278 DOI: 10.1016/j.jtct.2021.06.006 |
0.386 |
|
| 2021 |
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, ... ... Pidala JA, et al. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003502. PMID 33905264 DOI: 10.1200/JCO.20.03502 |
0.424 |
|
| 2021 |
Williams KM, Inamoto Y, Im A, Hamilton B, Koreth J, Arora M, Pusic I, Mays JW, Carpenter PA, Luznik L, Reddy P, Ritz J, Greinix H, Paczesny S, Blazar BR, ... Pidala J, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy. PMID 33877965 DOI: 10.1016/j.jtct.2021.02.035 |
0.358 |
|
| 2021 |
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine JE, Ayuk F, Dignan F, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy. PMID 33836313 DOI: 10.1016/j.jtct.2021.03.029 |
0.419 |
|
| 2021 |
Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, ... ... Pidala J, et al. Impact of total body irradiation based myeloablative conditioning regimen in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant: systematic review and meta-analysis. Transplantation and Cellular Therapy. PMID 33798768 DOI: 10.1016/j.jtct.2021.03.026 |
0.445 |
|
| 2021 |
Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, ... ... Pidala JA, et al. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 27: 256.e1-256.e7. PMID 33781526 DOI: 10.1016/j.jtct.2020.12.021 |
0.316 |
|
| 2021 |
Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, et al. Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: Preclinical and Phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33753457 DOI: 10.1158/1078-0432.CCR-20-4725 |
0.396 |
|
| 2021 |
Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation. PMID 33658647 DOI: 10.1038/s41409-021-01219-8 |
0.396 |
|
| 2021 |
Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, et al. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Advances. 5: 1154-1163. PMID 33635333 DOI: 10.1182/bloodadvances.2020003779 |
0.444 |
|
| 2021 |
Bhatt VR, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Badawy S, Beitinjaneh A, Lekakis LJ, Liu H, Maziarz RT, Modi D, Preussler J, Sharma A, Spellman SR, et al. Chronic Graft-Versus-Host Disease (cGVHD), Non-Relapse Mortality (NRM) and Disease Relapse in Older Vs. Younger Adult Recipients of Matched Sibling or Unrelated Donor Allogeneic Peripheral Blood Hematopoietic Cell Transplant (alloHCT): A CIBMTR Analysis Transplantation and Cellular Therapy. 27: S280-S281. DOI: 10.1016/S2666-6367(21)00358-4 |
0.449 |
|
| 2021 |
Perez AP, Kim J, Elmariah H, Bejanyan N, Padron E, Komrokji R, Kuykendall AT, Lancet JE, Sallman D, Faramand R, Perez LE, Pidala JA, Ochoa-Bayona J, Alsina M, Jain MD, et al. Allogeneic Hematopoietic Cell Transplant Outcomes for Chronic Myelomonocytic Leukemia: Single Center Experience Transplantation and Cellular Therapy. 27: S151-S152. DOI: 10.1016/S2666-6367(21)00188-3 |
0.395 |
|
| 2021 |
DeFilipp Z, Onstad L, Arai S, Arora M, Cutler C, Flowers ME, Kitko CL, Carpenter PA, Pidala JA, Alousi AM, Chen GL, Lee SJ, Hamilton BK. Non-Relapse Mortality Among Patients Diagnosed with Chronic Graft-Versus-Host Disease: An Updated Analysis from the Chronic Gvhd Consortium Transplantation and Cellular Therapy. 27: S79-S80. DOI: 10.1016/S2666-6367(21)00109-3 |
0.356 |
|
| 2021 |
Adoncecchi G, Kumar A, Faramand R, Liu H, Khimani F, Mishra A, Nieder ML, Nishihori T, Perez LE, Pidala JA, Anasetti C, Bejanyan N, Elmariah H. Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Patients Transplantation and Cellular Therapy. 27: S52-S53. DOI: 10.1016/S2666-6367(21)00081-6 |
0.388 |
|
| 2021 |
Lee CJ, Wang T, Chen K, Spellman SR, Kitko CL, MacMillan ML, Pidala JA, Auletta JJ, Badawy S, Battiwalla M, Bhatt VR, Buchbinder D, Cahn J, DeFilipp Z, Diaz MA, et al. First Late Effect in Pediatric Survivors with Chronic Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation for Hematologic Malignancy Transplantation and Cellular Therapy. 27: S40-S42. DOI: 10.1016/S2666-6367(21)00068-3 |
0.471 |
|
| 2021 |
Lee CJ, Wang T, Chen K, Spellman SR, Kitko CL, MacMillan ML, Pidala JA, Auletta JJ, Badawy S, Battiwalla M, Bhatt VR, Buchbinder D, Cahn J, DeFilipp Z, Diaz MA, et al. Impact of Chronic Graft-Versus-Host Disease on First Late Effect Among Adult Survivors of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis Transplantation and Cellular Therapy. 27: S39-S40. DOI: 10.1016/S2666-6367(21)00067-1 |
0.458 |
|
| 2020 |
Inamoto Y, Martin PJ, Lee SJ, Momin AA, Tabellini L, Onstad LE, Pidala J, Flowers MED, Lawler RL, Katayama H, Hanash S, Hansen JA. Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. Blood Advances. 4: 2409-2417. PMID 32492155 DOI: 10.1182/Bloodadvances.2020001485 |
0.423 |
|
| 2020 |
Pidala J, Bhatt VR, Hamilton B, Pusic I, Wood WA, Onstad L, Hall A, Storer B, Lee SJ. Ixazomib for treatment of refractory chronic graft vs. host disease: A Chronic GVHD Consortium phase II trial: Ixazomib for chronic GVHD treatment. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32464285 DOI: 10.1016/J.Bbmt.2020.05.015 |
0.439 |
|
| 2020 |
Gonzalez R, Pidala J. Evolving therapeutic options for chronic graft vs. host disease. Pharmacotherapy. PMID 32441379 DOI: 10.1002/Phar.2427 |
0.543 |
|
| 2020 |
Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Li G, Ghafoor T, Felices M, Miller J, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. The Journal of Clinical Investigation. PMID 32437331 DOI: 10.1172/Jci135754 |
0.373 |
|
| 2020 |
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32434056 DOI: 10.1016/J.Bbmt.2020.05.001 |
0.57 |
|
| 2020 |
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900396. PMID 32364845 DOI: 10.1200/Jco.19.00396 |
0.468 |
|
| 2020 |
Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. SOLE UPFRONT THERAPY WITH BECLOMETHASONE AND BUDESONIDE FOR UPPER GASTRO-INTESTINAL ACUTE GVHD: Topical therapy for upper gastrointestinal GVHD. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32361010 DOI: 10.1016/J.Bbmt.2020.04.023 |
0.43 |
|
| 2020 |
Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk J, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, et al. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. Jci Insight. PMID 32255769 DOI: 10.1172/Jci.Insight.136437 |
0.389 |
|
| 2020 |
DiMaggio E, Zhou JM, Caddell R, Tombleson R, Perkins J, Anasetti C, Khimani F, Pidala J, Nishihori T, Perez L, Betts B, Fernandez HF, Mishra A. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leukemia & Lymphoma. 1-10. PMID 32133897 DOI: 10.1080/10428194.2020.1731498 |
0.45 |
|
| 2020 |
Vinci C, Pidala J, Lau P, Reblin M, Jim H. A Mindfulness-Based Intervention for Caregivers of Allogeneic Hematopoietic Stem Cell Transplant Patients: Pilot Results. Psycho-Oncology. PMID 32043667 DOI: 10.1002/Pon.5353 |
0.454 |
|
| 2020 |
Otoukesh S, Elmariah H, Yang D, Mokhtari S, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Karanes C, Pidala J, Nakamura R, Anasetti C, Forman SJ, Al Malki MM, et al. Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Blood. 136: 10-11. DOI: 10.1182/BLOOD-2020-143166 |
0.414 |
|
| 2020 |
Adoncecchi G, Kumar A, Faramand R, Liu HD, Khimani F, Mishra A, Nieder M, Nishihori T, Perez L, Pidala J, Anasetti C, Bejanyan N, Elmariah H. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients Blood. 136: 27-27. DOI: 10.1182/BLOOD-2020-141966 |
0.408 |
|
| 2020 |
Shaw BE, Jimenez-Jimenez A, Burns LJ, Logan B, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang X, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, ... ... Pidala J, et al. Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative Blood. 136: 48-49. DOI: 10.1182/blood-2020-137677 |
0.387 |
|
| 2020 |
Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand R, Davila ML, Nieder M, Lawrence N, Lawrence H, Anasetti C, et al. Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results Blood. 136: 48-49. DOI: 10.1182/blood-2020-133874 |
0.337 |
|
| 2020 |
Elmariah H, Laborde J, Kim J, Gonzalez R, DiMaggio E, Nishihori T, Mishra A, Perez LE, Liu H, Khimani F, Ochoa-Bayona J, Faramand R, Baluch A, Nieder ML, Lazaryan A, ... ... Pidala JA, et al. The Effect of Mycophenolate Mofetil Dose per Kilogram on Clinical Outcomes of Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide Biology of Blood and Marrow Transplantation. 26: S189. DOI: 10.1016/j.bbmt.2019.12.754 |
0.407 |
|
| 2020 |
Mishra A, Thapa R, Bigam K, Extermann M, Faramand R, Khimani F, Wang X, Baracos V, Pidala JA. CT-Defined Fat Index Is a Prognostic Factor of Chronic Graft-Versus-Host Disease Outcomes in Adult Allogeneic Transplant Recipients Biology of Blood and Marrow Transplantation. 26: S183-S184. DOI: 10.1016/j.bbmt.2019.12.744 |
0.391 |
|
| 2020 |
Hashmi H, Lancet JE, Mishra A, Sweet K, Komrokji R, Fernandez H, Perez LE, Khimani F, Elmariah H, Pidala JA, Nieder ML, Bejanyan N, List AF, Anasetti C, Nishihori T. Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia – a Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.623 |
0.433 |
|
| 2020 |
Shaw BE, Burns LJ, Logan B, Jimenez-Jimenez AM, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang X, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, ... ... Pidala JA, et al. Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities Biology of Blood and Marrow Transplantation. 26: S283-S284. DOI: 10.1016/J.Bbmt.2019.12.553 |
0.476 |
|
| 2020 |
Ranspach P, Zhou J, Pidala JA, Nishihori T, Nieder ML, Elmariah H, Faramand R, Lazaryan A, Baluch A, Mishra A, Perez LE, Ochoa L, Liu H, Davila ML, Jain MD, et al. Delayed CD4+ T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.409 |
0.362 |
|
| 2020 |
Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, et al. A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.133 |
0.476 |
|
| 2020 |
Saliba RM, Arora M, Spellman SR, Hemmer MT, Wang T, Alousi AM, Pidala JA, Jagasia M, MacMillan ML, Horowitz MM, Schriber J, Champlin RE, Ciurea SO. Acute Graft-Versus-Host Disease Is Less Severe and Associated with Lower Non-Relapse Mortality after Haploidentical Transplantation with Post-Cyclophosphamide Prophylaxis Biology of Blood and Marrow Transplantation. 26: 26-27. DOI: 10.1016/J.Bbmt.2019.12.095 |
0.463 |
|
| 2019 |
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JL, Levine JE, Mielcarek M, Anasetti C, Antin JH, et al. Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501. Blood. PMID 31738834 DOI: 10.1182/Blood.2019003125 |
0.492 |
|
| 2019 |
Hamilton BK, Storer BE, Wood WA, Pidala JA, Cutler CS, Martin PJ, Chen G, Flowers ME, Lee SJ. Disability Related to Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31669175 DOI: 10.1016/j.bbmt.2019.10.019 |
0.341 |
|
| 2019 |
Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B. Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. Jama Oncology. PMID 31556923 DOI: 10.1001/Jamaoncol.2019.2974 |
0.474 |
|
| 2019 |
Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ. Carfilzomib for treatment of refractory chronic graft vs. host disease: A Chronic GVHD Consortium pilot phase II trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31499215 DOI: 10.1016/J.Bbmt.2019.09.002 |
0.435 |
|
| 2019 |
Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, Shaw BE, Fernández-Viña M, Burns LJ, Dehn J. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31419569 DOI: 10.1016/J.Bbmt.2019.08.002 |
0.467 |
|
| 2019 |
Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ. The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31394265 DOI: 10.1016/j.bbmt.2019.07.040 |
0.305 |
|
| 2019 |
Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina MA, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, ... Pidala J, et al. Selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR. Blood. PMID 31292117 DOI: 10.1182/Blood.2019001212 |
0.511 |
|
| 2019 |
Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe V, Antin JH, Sorror M, Shadman M, Press OW, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, et al. Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31253630 DOI: 10.1158/1078-0432.Ccr-18-3988 |
0.53 |
|
| 2019 |
Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, ... ... Pidala J, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances. 3: 1826-1836. PMID 31201170 DOI: 10.1182/Bloodadvances.2019000050 |
0.574 |
|
| 2019 |
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, et al. Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31158502 DOI: 10.1016/J.Bbmt.2019.05.019 |
0.425 |
|
| 2019 |
Hurley CK, Spellman S, Dehn J, Barker JN, Devine S, Fernandez-Vina M, Gautreaux M, Logan B, Maiers M, Mueller C, Perales MA, Yu N, Pidala J. Letter to the Editor regarding "Recipients receiving better HLA-matched hematopoietic cell transplantation grafts, uncovered by a novel HLA typing method, have superior survival: A retrospective study": 2019 May 2 Letter to the Editor Biology of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31145991 DOI: 10.1016/J.Bbmt.2019.05.026 |
0.528 |
|
| 2019 |
Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, et al. Impact of T-cell dose on the outcome of T-cell replete HLA matched allogeneic peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31085303 DOI: 10.1016/J.Bbmt.2019.05.007 |
0.428 |
|
| 2019 |
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, et al. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances. 3: 1441-1449. PMID 31053571 DOI: 10.1182/Bloodadvances.2018030171 |
0.506 |
|
| 2019 |
Hoogland AI, Nelson AM, Gonzalez BD, Small BJ, Breen EC, Sutton SK, Syrjala KL, Bower JE, Pidala J, Booth-Jones M, Jacobsen PB, Jim HSL. Worsening cognitive performance is associated with increases in systemic inflammation following hematopoietic cell transplantation. Brain, Behavior, and Immunity. PMID 30953767 DOI: 10.1016/J.Bbi.2019.04.008 |
0.479 |
|
| 2019 |
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, ... ... Pidala J, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). The Lancet. Haematology. 6: e132-e143. PMID 30824040 DOI: 10.1016/S2352-3026(18)30221-7 |
0.538 |
|
| 2019 |
Hoogland AI, Bulls HW, Gonzalez BD, Small BJ, Liu L, Pidala J, Jim HSL, Mishra A. Circadian rhythmicity as a predictor of quality of life in allogeneic hematopoietic cell transplant patients. Journal of Pain and Symptom Management. PMID 30711631 DOI: 10.1016/J.Jpainsymman.2019.01.015 |
0.355 |
|
| 2019 |
Dutta M, Mhaskar R, Elmariah H, Nishihori T, Shah B, Nieder M, Perez L, Faramand R, Pidala J, Bejanyan N, Khimani F. Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis Blood. 134: 4773-4773. DOI: 10.1182/Blood-2019-131126 |
0.502 |
|
| 2019 |
Chan O, Talati C, Asghari H, Bejanyan N, Elmariah H, Hussaini M, Khimani F, Kim J, Komrokji RS, Kuykendall AT, Lancet JE, List AF, Nieder M, Nishihori T, Padron E, ... ... Pidala J, et al. Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome Blood. 134: 4621-4621. DOI: 10.1182/Blood-2019-130922 |
0.467 |
|
| 2019 |
Elgarten CW, Li Y, Huang YV, Aplenc R, Hemmer MT, Arora M, Spellman SR, Wang T, Jagasia M, MacMillan ML, Pidala J, Fisher BT, Hall M. Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS) Blood. 134: 599-599. DOI: 10.1182/Blood-2019-130466 |
0.451 |
|
| 2019 |
Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Liu HD, Khimani F, Nieder M, Pidala J, Bejanyan N. CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide Blood. 134: 3329-3329. DOI: 10.1182/Blood-2019-129437 |
0.494 |
|
| 2019 |
Hashmi H, Lancet J, Mishra A, Sweet KL, Komrokji RS, Fernandez HF, Perez L, Khimani F, Nieder M, Elmariah H, Pidala J, Bejanyan N, List AF, Anasetti C, Nishihori T. Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience Blood. 134: 5739-5739. DOI: 10.1182/Blood-2019-128985 |
0.472 |
|
| 2019 |
Mirza S, Tandon A, Jenneman D, Cao S, Kumar A, Kidd MR, Khimani F, Mishra A, Liu HD, Nishihori T, Perez L, Bejanyan N, Pidala J, Nieder M, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Blood. 134: 5673-5673. DOI: 10.1182/Blood-2019-127370 |
0.524 |
|
| 2019 |
Koreth J, Chhabra S, Pidala J, Shea TC, Jagasia M, Waller EK, Nakamura R, Mielcarek M, Chen GL, Meyers G, Hoda D, Hamilton BK, Ng CT, Sonnemann M, Light S, et al. Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease Blood. 134: 4516-4516. DOI: 10.1182/Blood-2019-127325 |
0.416 |
|
| 2019 |
Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Ghafoor T, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia Blood. 134: 196-196. DOI: 10.1182/Blood-2019-124031 |
0.309 |
|
| 2019 |
Jayani R, Pidala J, Jim H, Zhou J, Mo Q, Mishra A. SELF-REPORTED PHYSICAL ACTIVITY IS PREDICTIVE OF SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) Hemasphere. 3: 714-715. DOI: 10.1097/01.HS9.0000564452.53633.54 |
0.328 |
|
| 2019 |
Asghari H, Mo Q, Naqvi SM, Lazaryan A, Davila ML, Nishihori T, Khimani F, Mishra A, Perez LE, Elmariah H, Liu H, Nieder ML, Fernandez H, Pidala JA, Anasetti C, et al. Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices Biology of Blood and Marrow Transplantation. 25: S124-S125. DOI: 10.1016/J.Bbmt.2018.12.406 |
0.378 |
|
| 2019 |
Hansen DK, Nieder ML, Thompson Z, Kim J, Pidala JA, Nishihori T, Khimani F, Davila ML, Mishra A, Lazaryan A, Sallman D, Elmariah H, Sweet K, Liu H, Perez LE, et al. ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 25: S112. DOI: 10.1016/J.Bbmt.2018.12.388 |
0.335 |
|
| 2019 |
Pidala JA, Hamadani M, Dawson P, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara J, Levine JE, Anasetti C, Pritchard T, Martens M, Horowitz MM, et al. Sirolimus Vs. Prednisone As Initial Systemic Therapy for Minnesota Standard Risk (MN-SR), Ann Arbor 1/2 Acute Graft-Vs-Host Disease (GVHD): Primary Results of the Multi-Center Randomized Phase II BMT CTN 1501 Trial Biology of Blood and Marrow Transplantation. 25: S50-S51. DOI: 10.1016/J.BBMT.2018.12.128 |
0.309 |
|
| 2019 |
Pidala JA, Mupfudze TG, Payton T, Barker JN, Perales M, Shaw BE, Fernández-Viña M, Burns LJ, Dehn J. What Defines an Urgent Time to Transplant (TtT)? a National Marrow Donor Program (NMDP) Survey of Transplant Physicians and Search Coordinators’ Unrelated Donor Selection Practices Biology of Blood and Marrow Transplantation. 25: S36. DOI: 10.1016/J.BBMT.2018.12.109 |
0.357 |
|
| 2018 |
Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CA, Frieling J, et al. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Frontiers in Immunology. 9: 2887. PMID 30574153 DOI: 10.3389/Fimmu.2018.02887 |
0.396 |
|
| 2018 |
Vinci C, Reblin M, Jim H, Pidala J, Bulls H, Cutolo E. Understanding preferences for a mindfulness-based stress management program among caregivers of hematopoietic cell transplant patients. Complementary Therapies in Clinical Practice. 33: 164-169. PMID 30396616 DOI: 10.1016/J.Ctcp.2018.10.007 |
0.33 |
|
| 2018 |
Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, et al. Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease in North America. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30296479 DOI: 10.1016/j.bbmt.2018.09.040 |
0.307 |
|
| 2018 |
Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini PN, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, et al. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30292009 DOI: 10.1016/J.Bbmt.2018.09.004 |
0.455 |
|
| 2018 |
Gandelman JS, Byrne MT, Mistry AM, Polikowsky HG, Diggins KE, Chen H, Lee SJ, Arora M, Cutler C, Flowers M, Pidala J, Irish JM, Jagasia MH. Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. Haematologica. PMID 30237265 DOI: 10.3324/Haematol.2018.193441 |
0.438 |
|
| 2018 |
Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER. The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30219700 DOI: 10.1016/J.Bbmt.2018.09.007 |
0.382 |
|
| 2018 |
Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes CJM, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, et al. Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30194027 DOI: 10.1016/J.Bbmt.2018.08.029 |
0.552 |
|
| 2018 |
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30153491 DOI: 10.1016/j.bbmt.2018.08.018 |
0.424 |
|
| 2018 |
Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR. Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30144561 DOI: 10.1016/J.Bbmt.2018.08.011 |
0.536 |
|
| 2018 |
Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, ... ... Pidala J, et al. Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Advances. 2: 1882-1888. PMID 30087106 DOI: 10.1182/Bloodadvances.2018017343 |
0.448 |
|
| 2018 |
Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, ... ... Pidala J, et al. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. PMID 30076185 DOI: 10.3324/Haematol.2017.182550 |
0.538 |
|
| 2018 |
Arrieta-Bolaños E, Crivello P, Shaw BE, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. Blood Advances. 2: 1773-1783. PMID 30042143 DOI: 10.1182/Bloodadvances.2018019620 |
0.499 |
|
| 2018 |
El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, Palmer J, Flowers ME, Jagasia M, Chen YB, Lee SJ. Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30031937 DOI: 10.1016/J.Bbmt.2018.07.020 |
0.477 |
|
| 2018 |
Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplantation. PMID 29895929 DOI: 10.1038/S41409-018-0233-2 |
0.465 |
|
| 2018 |
Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, et al. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances. 2: 1022-1031. PMID 29739773 DOI: 10.1182/bloodadvances.2017013052 |
0.434 |
|
| 2018 |
Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, et al. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplantation. PMID 29670210 DOI: 10.1038/S41409-018-0163-Z |
0.375 |
|
| 2018 |
Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, ... ... Pidala J, et al. ASBMT Practice Guidelines Committee Survey on Long Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29608957 DOI: 10.1016/J.Bbmt.2018.03.023 |
0.422 |
|
| 2018 |
Lee SJ, Hamilton BK, Pidala J, Alousi A, Kurukulasuriya C, Onstad L, Jagasia M, Chen G, Cutler C, Brody R, Arora M, Arai S, Sarantopoulos S, Flowers ME. Design and Patient Characteristics of the Chronic Graft-Versus-Host Disease Response Measures Validation Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29476954 DOI: 10.1016/J.Bbmt.2018.02.010 |
0.455 |
|
| 2018 |
Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, et al. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29454040 DOI: 10.1016/J.Bbmt.2018.02.006 |
0.498 |
|
| 2018 |
Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, et al. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 29382954 DOI: 10.1038/S41409-018-0100-1 |
0.501 |
|
| 2018 |
Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, ... ... Pidala J, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America. PMID 29382747 DOI: 10.1073/Pnas.1712452115 |
0.507 |
|
| 2018 |
Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. British Journal of Haematology. PMID 29345306 DOI: 10.1111/Bjh.15105 |
0.493 |
|
| 2018 |
Khera N, Hamilton BK, Wood WA, Wu V, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Pidala JA, et al. Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 24: S30-S31. DOI: 10.1016/J.BBMT.2017.12.587 |
0.334 |
|
| 2018 |
Chahal N, Hoogland AI, Jim HS, Pidala JA. Depression, Sleep, Fatigue, and Physical Activity in a Randomized Trial of Ustekinumab for Prevention of Acute Graft Versus Host Disease Following Hematopoietic Cell Transplant Biology of Blood and Marrow Transplantation. 24: S259-S260. DOI: 10.1016/J.BBMT.2017.12.191 |
0.336 |
|
| 2018 |
Hamilton BK, Liu Y, Hemmer M, Wang T, Chhabra S, Costa LJ, Kim DD, Ringden O, Stuart RK, Alousi AM, Couriel DR, Pidala JA, Spellman SR, Majhail NS, Arora M. Cyclosporine in Combination with Mycophenolate Mofetil Leads to Increased Incidence of Graft-Versus-Host Disease and Inferior Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.137 |
0.451 |
|
| 2018 |
Holtan SG, Defor TE, Howard A, Pidala JA, Levine JE, Wu JM, Khera N, Lee SJ, Bolaños-Meade J, Ho VT, Alousi AM, Inamoto Y, Chen GL, Arora M, Palmer J, et al. Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.128 |
0.339 |
|
| 2018 |
Chhabra S, Liu Y, Hemmer MT, Wang T, Hamilton BK, Costa LJ, Kim DD, Majhail NS, Stuart RK, Alousi AM, Couriel DR, Pidala JA, Spellman SR, Ringden O, Arora M. Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation: Comparing the Efficacy of Mycophenolate Mofetil and Methotrexate in Combination with Calcineurin Inhibitor Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.119 |
0.433 |
|
| 2017 |
Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, et al. In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. PMID 29242294 DOI: 10.3324/Haematol.2017.171199 |
0.446 |
|
| 2017 |
Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljuf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, et al. Influence of Age on Acute and Chronic GVHD in Children Receiving HLA-Identical Sibling BMT for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29155316 DOI: 10.1016/J.Bbmt.2017.11.004 |
0.523 |
|
| 2017 |
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, ... ... Pidala JA, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017758177. PMID 29040031 DOI: 10.1200/JCO.2017.75.8177 |
0.426 |
|
| 2017 |
Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, Jagasia M, Martin PJ, Palmer J, Pidala J, Majhail NS, Lee SJ, Khera N. Association of Socioeconomic Status with Chronic Graft-Versus-Host Disease Outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29032275 DOI: 10.1016/J.Bbmt.2017.10.009 |
0.473 |
|
| 2017 |
Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, ... ... Pidala J, et al. Hypoalbuminemia at Day +90 is Associated with Inferior Non-Relapse Mortality and Overall Survival in Allogeneic HCT Recipients: a Confirmatory Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29032266 DOI: 10.1016/J.Bbmt.2017.09.022 |
0.522 |
|
| 2017 |
Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, Müller C, Verneris M, Shaw BE, Pidala J, Oudshorn M, Lee SJ, Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 28581467 DOI: 10.1038/Bmt.2017.96 |
0.52 |
|
| 2017 |
Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler C, Lee SJ. An endpoint associated with clinical benefit after initial treatment for chronic graft-versus-host disease. Blood. PMID 28495794 DOI: 10.1182/Blood-2017-03-775767 |
0.44 |
|
| 2017 |
Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM. Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. American Journal of Epidemiology. PMID 28472335 DOI: 10.1093/Aje/Kwx027 |
0.415 |
|
| 2017 |
Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, ... Pidala J, et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplantation. PMID 28368376 DOI: 10.1038/Bmt.2017.63 |
0.523 |
|
| 2017 |
Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, ... ... Pidala J, et al. Improved survival after acute graft vs host disease diagnosis in the modern era. Haematologica. PMID 28302712 DOI: 10.3324/Haematol.2016.156356 |
0.53 |
|
| 2017 |
Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. PMID 28104702 DOI: 10.3324/Haematol.2016.153072 |
0.519 |
|
| 2017 |
Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Science Translational Medicine. 9. PMID 28077684 DOI: 10.1126/Scitranslmed.Aai8269 |
0.365 |
|
| 2017 |
Shaw BE, Logan BR, Spellman SR, Marsh SG, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter DL, Petersdorf EW, Woolfrey A, et al. Analysis of 10,462 8/8 HLA- Matched Unrelated Donor Transplants Could Not Identify a Donor Selection Score, As Younger Age Is the Only Significant Donor Characteristic Associated with Survival Blood. 130: 848-848. DOI: 10.1182/Blood.V130.Suppl_1.848.848 |
0.494 |
|
| 2017 |
Holtan SG, DeFor TE, Pidala J, Khera N, Lee SJ, Howard A, Wu J, Bolanos-Meade FJ, Ho VT, Alousi AM, Inamoto Y, Chen G, Arora M, Palmer J, Flowers ME, et al. Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802 Blood. 130: 72-72. DOI: 10.1182/Blood.V130.Suppl_1.72.72 |
0.439 |
|
| 2017 |
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Weisdorf DJ. Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients Blood. 130: 2053-2053. DOI: 10.1182/Blood.V130.Suppl_1.2053.2053 |
0.562 |
|
| 2017 |
Hamilton BK, Rybicki L, Arora M, Arai S, Cutler CS, Flowers ME, Martin PJ, Palmer J, Pidala JA, Majhail NS, Lee SJ, Khera N. Association of Socioeconomic Status (SES) with Chronic Graft-Versus-Host Disease (cGVHD) Outcomes Biology of Blood and Marrow Transplantation. 23: S25. DOI: 10.1016/J.BBMT.2016.12.078 |
0.31 |
|
| 2016 |
Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, et al. CD25 Blockade Delays Treg Reconstitution and Does Not Prevent Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28007665 DOI: 10.1016/J.Bbmt.2016.12.624 |
0.506 |
|
| 2016 |
Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplantation. PMID 27991896 DOI: 10.1038/Bmt.2016.330 |
0.522 |
|
| 2016 |
Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplantation. PMID 27941764 DOI: 10.1038/Bmt.2016.265 |
0.516 |
|
| 2016 |
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, ... ... Pidala J, et al. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplantation. PMID 27819684 DOI: 10.1038/Bmt.2016.269 |
0.564 |
|
| 2016 |
Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers ME, Cutler CS, Lukez A, Arai S, ... ... Pidala J, et al. Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. PMID 27625357 DOI: 10.1182/Blood-2015-09-669846 |
0.516 |
|
| 2016 |
Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Crothers K, Pusic I, Lee SJ, Williams KM. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Annals of the American Thoracic Society. PMID 27513368 DOI: 10.1513/Annalsats.201604-262Oc |
0.404 |
|
| 2016 |
Pidala J, Anasetti C. Predicting relevant immunogenetic disparities. Blood. 128: 12-3. PMID 27389541 DOI: 10.1182/Blood-2016-05-717512 |
0.46 |
|
| 2016 |
Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, et al. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: A report from the Center for International Blood and Marrow Transplant Research. Haematologica. PMID 27247320 DOI: 10.3324/Haematol.2016.143271 |
0.471 |
|
| 2016 |
Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala J, Hamilton BK, et al. Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217465 DOI: 10.1200/Jco.2015.65.9615 |
0.514 |
|
| 2016 |
Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes? Bone Marrow Transplantation. PMID 27088383 DOI: 10.1038/Bmt.2016.105 |
0.386 |
|
| 2016 |
Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, Lee SJ, Wolff D, Subrt P, Abdossamadi S, Sung S, Storek J, Levings M, Aljurf M, Arora M, ... ... Pidala J, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: the only consistent association is with CXCL10 and CXCR3+ NK cells. Blood. PMID 27020088 DOI: 10.1182/Blood-2015-09-668251 |
0.394 |
|
| 2016 |
Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, et al. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 319-27. PMID 26378033 DOI: 10.1158/1078-0432.Ccr-15-1443 |
0.516 |
|
| 2016 |
Kumar AJ, Kim S, Hemmer M, Arora M, Spellman S, Pidala JA, Couriel D, Alousi AM, Loren AW. Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes Blood. 128: 70-70. DOI: 10.1182/blood.v128.22.70.70 |
0.455 |
|
| 2016 |
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Jagasia MH, Shaughnessy PJ, Gergis U, ... ... Pidala JA, et al. A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT) Blood. 128: 505-505. DOI: 10.1182/BLOOD.V128.22.505.505 |
0.434 |
|
| 2016 |
Caddell RJ, Schaible B, Ma Z, Dimaggio E, Tombleson R, Anasetti C, Ayala E, Betts BC, Kharfan-Dabaja MA, Locke FL, Nishihori T, Pidala JA, Fernandez HF, Mishra A. Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS Blood. 128: 3486-3486. DOI: 10.1182/BLOOD.V128.22.3486.3486 |
0.441 |
|
| 2016 |
Qayed M, Horan J, Spellman SR, Arora M, Wang T, Hemmer M, Pidala JA, Couriel D, Alousi AM. Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation Blood. 128: 2228-2228. DOI: 10.1182/Blood.V128.22.2228.2228 |
0.379 |
|
| 2016 |
Khimani F, Dean E, Rizk V, Kim J, Chen L, Nishihori T, Kharfan-Dabaja M, Betts B, Mishra A, Ayala E, Locke FL, Field T, Ochoa-Bayona JL, Perez LE, Nieder ML, ... ... Pidala JA, et al. Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non-Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease Prevention Biology of Blood and Marrow Transplantation. 22: S402-S403. DOI: 10.1016/j.bbmt.2015.11.930 |
0.319 |
|
| 2016 |
Mishra A, Pidala JA, Betts B, Fernandez H, Nishihori T, Extermann M, Jim H, Anasetti C, Xiong Y, Magliocco A. Body Composition Predicts for Survival in Allogeneic (allo) Hematopoietic Stem Cell Transplantation (HCT) Recipients Biology of Blood and Marrow Transplantation. 22: S69. DOI: 10.1016/j.bbmt.2015.11.361 |
0.375 |
|
| 2015 |
Yuan A, Chai X, Martins F, Arai S, Arora M, Correa ME, Pidala J, Cutler C, Lee SJ, Treister NS. Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. Oral Diseases. PMID 26708609 DOI: 10.1111/Odi.12429 |
0.447 |
|
| 2015 |
Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers ME, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, et al. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26541363 DOI: 10.1016/J.Bbmt.2015.10.018 |
0.57 |
|
| 2015 |
Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ. Predictors of survival, non-relapse mortality and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. PMID 26527676 DOI: 10.1182/Blood-2015-08-662874 |
0.451 |
|
| 2015 |
Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, et al. FAM treatment for new onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26475726 DOI: 10.1016/J.Bbmt.2015.10.009 |
0.439 |
|
| 2015 |
Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu XZ. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. Plos One. 10: e0137641. PMID 26348529 DOI: 10.1371/Journal.Pone.0137641 |
0.464 |
|
| 2015 |
Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, et al. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplantation. PMID 26301969 DOI: 10.1038/Bmt.2015.192 |
0.503 |
|
| 2015 |
Verneris MR, Lee SJ, Ahn KW, Wang HL, Battiwalla M, Inamoto Y, Fernandez-Vina MA, Gajewski J, Pidala J, Munker R, Aljurf M, Saber W, Spellman S, Koreth J. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26055300 DOI: 10.1016/J.Bbmt.2015.05.028 |
0.554 |
|
| 2015 |
Sun YC, Chai X, Inamoto Y, Pidala J, Martin PJ, Flowers ME, Shen TT, Lee SJ, Jagasia M. Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26033283 DOI: 10.1016/J.Bbmt.2015.05.020 |
0.523 |
|
| 2015 |
Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, et al. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 100: 970-7. PMID 25840599 DOI: 10.3324/Haematol.2015.123588 |
0.581 |
|
| 2015 |
Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1074-82. PMID 25805300 DOI: 10.1016/J.Bbmt.2015.03.014 |
0.375 |
|
| 2015 |
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 984-99. PMID 25796139 DOI: 10.1016/J.Bbmt.2015.02.025 |
0.38 |
|
| 2015 |
Pidala J, Bloom GC, Eschrich S, Sarwal M, Enkemann S, Betts BC, Beato F, Yoder S, Anasetti C. Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. Plos One. 10: e0117001. PMID 25774806 DOI: 10.1016/J.Bbmt.2011.12.067 |
0.39 |
|
| 2015 |
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, Arai S, Flowers ME, Lee SJ. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica. 100: 690-5. PMID 25715403 DOI: 10.3324/Haematol.2014.117283 |
0.477 |
|
| 2015 |
Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of Leukocyte Biology. 97: 807-19. PMID 25663681 DOI: 10.1189/Jlb.5A1114-532Rr |
0.416 |
|
| 2015 |
Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, Hansen J, Jagasia M, Miklos D, Pavletic S, Parkman R, Russek-Cohen E, Flowers ME, Lee S, Martin P, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 780-92. PMID 25644957 DOI: 10.1016/J.Bbmt.2015.01.003 |
0.448 |
|
| 2015 |
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, ... ... Pidala JA, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 266-74. PMID 25445023 DOI: 10.1016/J.Bbmt.2014.10.021 |
0.466 |
|
| 2015 |
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, ... ... Pidala JA, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 151-8. PMID 25316109 DOI: 10.1016/j.bbmt.2014.10.006 |
0.415 |
|
| 2015 |
Mishra A, Yue B, Kim J, Anasetti C, Pidala JA, Riches ML, Jim HS. Physical activity as a predictor of outcomes in hematopoietic stem cell transplantation (HSCT) recipients. Journal of Clinical Oncology. 33: 7027-7027. DOI: 10.1200/JCO.2015.33.15_SUPPL.7027 |
0.349 |
|
| 2015 |
Nikiforow S, Hemmer M, Spellman SR, Alousi AM, Couriel DR, Pidala JA, Arora M, Cutler CS, Wang T. Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations Blood. 126: 857-857. DOI: 10.1182/Blood.V126.23.857.857 |
0.458 |
|
| 2015 |
Khimani F, Jeong DK, Nishihori T, Ayala E, Pidala JA, Locke FL, Kenneth G, Chavez JC, Anasetti C, Kharfan-Dabaja MA. Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies Blood. 126: 5524-5524. DOI: 10.1182/blood.v126.23.5524.5524 |
0.327 |
|
| 2015 |
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Orti G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, ... ... Pidala JA, et al. An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation Blood. 126: 3142-3142. DOI: 10.1182/BLOOD.V126.23.3142.3142 |
0.494 |
|
| 2015 |
Mishra A, Yue B, Extermann M, Anasetti C, Jim H, Kim J, Pidala JA, Baracos VE. Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients Blood. 126: 2113-2113. DOI: 10.1182/blood.V126.23.2113.2113 |
0.345 |
|
| 2015 |
Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, et al. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience Bone Marrow Transplantation. DOI: 10.1038/bmt.2015.192 |
0.408 |
|
| 2015 |
Wood WA, Lee SJ, Chai X, Flowers MED, Cutler CS, Inamoto Y, Lazaryan A, Pidala J, Palmer J, Martin PJ. Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.560 |
0.448 |
|
| 2015 |
Pidala J, Beato F, Kim J, Alsina M, Ayala E, Betts B, Fernandez H, Field T, Jim H, Kelley L, Kharfan-Dabaja M, Locke FL, Mishra A, Nieder ML, Nishihori T, et al. IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease Biology of Blood and Marrow Transplantation. 21: S344-S345. DOI: 10.1016/J.Bbmt.2014.11.548 |
0.383 |
|
| 2015 |
Pidala J, Kim J, Yue B, Betts B, Alsina M, Ayala E, Fernandez H, Field T, Kelley L, Kharfan-Dabaja M, Locke FL, Mishra A, Nieder ML, Nishihori T, Ochoa-Bayona J, et al. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft Vs. Host Disease Biology of Blood and Marrow Transplantation. 21: S343-S344. DOI: 10.1016/J.Bbmt.2014.11.547 |
0.455 |
|
| 2015 |
Khera N, Chai X, Duong HK, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Jagasia MH, Pusic I, ... ... Pidala J, et al. Prospective Longitudinal Study of Late Acute Graft Versus Host Disease after Hematopoietic Cell Transplantation: A Report from Chronic GVHD Consortium Biology of Blood and Marrow Transplantation. 21: 336-337. DOI: 10.1016/J.Bbmt.2014.11.536 |
0.557 |
|
| 2015 |
Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, et al. A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.516 |
0.481 |
|
| 2015 |
Cheng G, Pusic I, Jagasia MH, Burns LJ, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chai X, Lee SJ, Williams KM. BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.253 |
0.309 |
|
| 2015 |
Williams KM, Cheng G, Pusic I, Jagasia MH, Burns LJ, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Jacobsohn DA, Martin PJ, Storer BE, Inamoto Y, Chai X, et al. Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.062 |
0.399 |
|
| 2015 |
Palmer J, Chai X, Martin PJ, Pidala J, Lazaryan A, Arora M, Cutler CS, Pavletic SZ, Pusic I, Jagasia MH, Inamoto Y, Flowers MED, Vogelsang G, Lee SJ. Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.059 |
0.374 |
|
| 2015 |
Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers MED, Inamoto Y, Chen GL, Wood B, Khera N, Palmer J, Duong HK, Arai S, Lee SJ. Incidence, Risk Factors, and Prognosis of Late Immune-Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation (HCT) Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.052 |
0.442 |
|
| 2014 |
Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 124: 2596-606. PMID 25161269 DOI: 10.1182/Blood-2014-05-576041 |
0.482 |
|
| 2014 |
Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane Database of Systematic Reviews. 7: CD010280. PMID 25061777 DOI: 10.1002/14651858.Cd010280.Pub2 |
0.46 |
|
| 2014 |
Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, Flowers ME, Arora M, Jagasia M, Arai S, Chai X, Pavletic SZ, Vogelsang GB, Lee SJ. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 99: 1618-23. PMID 24997150 DOI: 10.3324/Haematol.2014.109611 |
0.428 |
|
| 2014 |
Jim HS, Quinn GP, Barata A, Cases M, Cessna J, Gonzalez B, Gonzalez L, Koskan A, Montiel-Ishino F, Pidala J. Caregivers' quality of life after blood and marrow transplantation: a qualitative study. Bone Marrow Transplantation. 49: 1234-6. PMID 24887387 DOI: 10.1038/Bmt.2014.118 |
0.41 |
|
| 2014 |
El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, et al. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1341-8. PMID 24813171 DOI: 10.1016/J.Bbmt.2014.05.001 |
0.497 |
|
| 2014 |
Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, Palmer J, Arai S, Jacobsohn D, Cutler C, Jagasia M, Goldberg JD, Martin PJ, Pavletic SZ, Vogelsang GB, et al. Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis & Rheumatology (Hoboken, N.J.). 66: 1044-52. PMID 24757155 DOI: 10.1002/Art.38293 |
0.497 |
|
| 2014 |
Jim HS, Evans B, Jeong JM, Gonzalez BD, Johnston L, Nelson AM, Kesler S, Phillips KM, Barata A, Pidala J, Palesh O. Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1465-84. PMID 24747335 DOI: 10.1016/J.Bbmt.2014.04.010 |
0.318 |
|
| 2014 |
McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, ... ... Pidala J, et al. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 960-8. PMID 24641829 DOI: 10.1016/J.Bbmt.2014.03.013 |
0.406 |
|
| 2014 |
Inamoto Y, Jagasia M, Wood WA, Pidala J, Palmer J, Khera N, Weisdorf D, Carpenter PA, Flowers ME, Jacobsohn D, Martin PJ, Lee SJ, Pavletic SZ. Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplantation. 49: 532-8. PMID 24464142 DOI: 10.1038/Bmt.2013.225 |
0.367 |
|
| 2014 |
Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 600-16. PMID 24462742 DOI: 10.1016/J.Bbmt.2014.01.019 |
0.341 |
|
| 2014 |
Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY, Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplantation. 49: 477-84. PMID 24419521 DOI: 10.1038/Bmt.2013.211 |
0.419 |
|
| 2014 |
Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 337-44. PMID 24315845 DOI: 10.1016/J.Bbmt.2013.11.025 |
0.389 |
|
| 2014 |
Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J. Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial. Haematologica. 99: 548-53. PMID 24241491 DOI: 10.3324/Haematol.2013.088781 |
0.477 |
|
| 2014 |
Jim HS, Quinn GP, Gwede CK, Cases MG, Barata A, Cessna J, Christie J, Gonzalez L, Koskan A, Pidala J. Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life. Bone Marrow Transplantation. 49: 299-303. PMID 24121210 DOI: 10.1038/Bmt.2013.158 |
0.383 |
|
| 2014 |
Betts BC, Veerapathran A, Pidala J, Yu XZ, Anasetti C. STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. Journal of Leukocyte Biology. 95: 205-13. PMID 24068731 DOI: 10.1189/Jlb.0313154 |
0.372 |
|
| 2014 |
Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN, Brunstein CG, Gibson J, Kebriaei P, Lazarus HM, Olsson R, Perales MA, Pidala J, Savani B, Rocha V, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica. 99: 322-8. PMID 24056817 DOI: 10.3324/Haematol.2013.094193 |
0.515 |
|
| 2014 |
Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplantation. 49: 11-6. PMID 23995098 DOI: 10.1038/Bmt.2013.121 |
0.553 |
|
| 2014 |
Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, ... ... Pidala J, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 28: 658-65. PMID 23989431 DOI: 10.1038/Leu.2013.253 |
0.481 |
|
| 2014 |
Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic markers of chronic GVHD Bone Marrow Transplantation. 49: 324-331. PMID 23872737 DOI: 10.1038/Bmt.2013.97 |
0.338 |
|
| 2014 |
Betts BC, Veerapathran A, Beato F, Lawrence HR, Sebti SM, Pidala JA, Anasetti C. CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses Blood. 124: 3819-3819. DOI: 10.1182/Blood.V124.21.3819.3819 |
0.315 |
|
| 2014 |
Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Riches ML, Anasetti C. Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease Blood. 124: 2502-2502. DOI: 10.1182/Blood.V124.21.2502.2502 |
0.555 |
|
| 2014 |
Frairia C, Shapiro J, Kim J, Pidala J, Ayala E, Betts BC, Fernandez HF, Field T, Kharfan-Dabaja M, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Riches ML, et al. Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd Blood. 124: 2500-2500. DOI: 10.1182/Blood.V124.21.2500.2500 |
0.473 |
|
| 2014 |
Tees MT, Betts BC, Fernandez HF, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Riches ML. Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis Blood. 124: 2475-2475. DOI: 10.1182/Blood.V124.21.2475.2475 |
0.422 |
|
| 2014 |
Jagasia MH, Chai X, Pidala J, Inamoto Y, Arora M, Cutler CS, Flowers MED, Johnston L, Pavletic SZ, Lee SJ. Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.453 |
0.364 |
|
| 2014 |
Field T, Perkins J, Hillgruber R, Nishihori T, Tomblyn MR, Mishra A, Pidala J, Locke F, Perez LE, Betts B, Ayala E, Alsina M, Ochoa J, Padron E, Lancet J, et al. Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.374 |
0.536 |
|
| 2014 |
Ayala E, Tomblyn MR, Kharfan-Dabaja M, Locke F, Nishihori T, Field T, Fernandez H, Pidala J, Betts B, Mishra A, Ochoa J, Perez LE, Anasetti C, Alsina M. High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Early during the Course of Disease Appears to Improve Outcomes of Patients T Cell Non-Hodgkin Lymphoma: Results of a Single-Institution Experience Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.253 |
0.47 |
|
| 2014 |
Jim H, Quinn G, Barata A, Cases M, Cessna J, Flynn A, Gonzalez B, Gonzalez L, Gwede C, Koskan A, Montiel-Ishino F, Pidala J. Providing Care to a Hematopoietic CELL Transplant Recipient: Caregivers Describe Their Own Quality of Life Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.232 |
0.418 |
|
| 2014 |
El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski S, Lee SJ, Chen Y. The Impact of Age on Quality of Life, Functional Status, and Overall Survival in Patients with Moderate-Severe Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.074 |
0.444 |
|
| 2014 |
Duncan C, Majhail NS, Brazauskas R, Wang Z, Cahn J, Kamble RT, Frangoul HA, Hayashi RJ, Hsu JW, Jacobsohn DA, Kasow KA, Khera N, Lazarus HM, Loren AW, Maziarz RT, ... ... Pidala J, et al. Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.073 |
0.476 |
|
| 2014 |
Pidala J, Lee SJ, Spellman SR, Wang H, Ahn KW, Aljurf MD, Askar M, Dehn J, Viña MAF, Gratwohl A, Gupta V, Hanna R, Hurley CK, Inamoto Y, Kassim AA, et al. HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A Cibmtr Analysis Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.008 |
0.491 |
|
| 2013 |
Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 122: 3651-8. PMID 23982174 DOI: 10.1182/Blood-2013-05-501510 |
0.443 |
|
| 2013 |
Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 122: 2251-61. PMID 23908471 DOI: 10.1182/Blood-2013-03-492397 |
0.426 |
|
| 2013 |
Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2662-70. PMID 23797000 DOI: 10.1200/Jco.2012.46.8652 |
0.496 |
|
| 2013 |
Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer JM, Arora M, Arai S, Jagasia M, Storer B, Lee SJ, et al. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplantation. 48: 1429-36. PMID 23665819 DOI: 10.1038/Bmt.2013.70 |
0.519 |
|
| 2013 |
Phillips KM, McGinty HL, Cessna J, Asvat Y, Gonzalez B, Cases MG, Small BJ, Jacobsen PB, Pidala J, Jim HS. A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation. Bone Marrow Transplantation. 48: 1350-7. PMID 23645166 DOI: 10.1016/J.Bbmt.2012.11.248 |
0.382 |
|
| 2013 |
El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 5: 457-66. PMID 23638742 DOI: 10.2217/Imt.13.31 |
0.502 |
|
| 2013 |
Hurley CK, Woolfrey A, Wang T, Haagenson M, Umejiego J, Aljurf M, Askar M, Battiwalla M, Dehn J, Horan J, Oudshoorn M, Pidala J, Saber W, Turner V, Lee SJ, et al. The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. Blood. 121: 4800-6. PMID 23637130 DOI: 10.1182/Blood-2013-01-480343 |
0.51 |
|
| 2013 |
Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 1087-93. PMID 23632090 DOI: 10.1016/J.Bbmt.2013.04.020 |
0.433 |
|
| 2013 |
Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ. Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 967-72. PMID 23542686 DOI: 10.1016/J.Bbmt.2013.03.014 |
0.463 |
|
| 2013 |
Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplantation. 48: 1179-84. PMID 23542223 DOI: 10.1038/Bmt.2013.37 |
0.499 |
|
| 2013 |
Loren AW, Brazauskas R, Chow EJ, Gilleece M, Halter J, Jacobsohn DA, Joshi S, Pidala J, Quinn GP, Wang Z, Apperley JF, Burns LJ, Hale GA, Hayes-Lattin BM, Kamble R, et al. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplantation. 48: 1091-7. PMID 23419436 DOI: 10.1038/Bmt.2013.13 |
0.372 |
|
| 2013 |
Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers ME, Palmer J, Khera N, Jagasia M, Cutler C, Arora M, Vogelsang G, Lee SJ. Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 784-91. PMID 23395601 DOI: 10.1016/J.Bbmt.2013.02.001 |
0.439 |
|
| 2013 |
Treister N, Chai X, Kurland B, Pavletic S, Weisdorf D, Pidala J, Palmer J, Martin P, Inamoto Y, Arora M, Flowers M, Jacobsohn D, Jagasia M, Arai S, Lee SJ, et al. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. Bone Marrow Transplantation. 48: 1123-8. PMID 23353804 DOI: 10.1038/Bmt.2012.285 |
0.325 |
|
| 2013 |
Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, Pavletic SZ, Palmer J, Vogelsang G, Jagasia M, Schultz K, Lee SJ. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 27: 1196-201. PMID 23047477 DOI: 10.1038/Leu.2012.292 |
0.533 |
|
| 2013 |
Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplantation. 48: 346-50. PMID 22863723 DOI: 10.1038/Bmt.2012.150 |
0.424 |
|
| 2013 |
Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 48: 63-7. PMID 22705801 DOI: 10.1016/J.Bbmt.2011.12.376 |
0.384 |
|
| 2013 |
Perez L, Field T, Riches ML, Fernandez HF, Locke FL, Betts BC, Pidala J, Elmer E, Beato F, Lienlaf M, Horna P, Villagra A, Anasetti C. A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease Blood. 122: 3308-3308. DOI: 10.1182/Blood.V124.21.1167.1167 |
0.441 |
|
| 2013 |
El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski SM, Lee SJ, Chen Y. Do Older Patients With Moderate-Severe Chronic Graft-Versus-Host Disease Differ From Younger Patients? Blood. 122: 725-725. DOI: 10.1182/Blood.V122.21.725.725 |
0.497 |
|
| 2013 |
Koreth J, Ahn KW, Pidala J, Gajewski JL, Wang H, Viña MAF, Spellman S, Lee SJ. HLA-Mismatch Is Associated With Worse Outcomes After Unrelated Donor Reduced Intensity Conditioning Hematopoietic Cell Transplantation: A Cibmtr Analysis Blood. 122: 547-547. DOI: 10.1182/Blood.V122.21.547.547 |
0.537 |
|
| 2013 |
Inamoto Y, Storer BE, Weisdorf DJ, Vogelsang GB, Pidala J, Chai X, Flowers MED, Arora M, Arai S, Palmer J, Cutler CS, Jagasia M, Pavletic SZ, Lee SJ, Martin PJ. Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium Blood. 122: 4614-4614. DOI: 10.1182/Blood.V122.21.4614.4614 |
0.387 |
|
| 2013 |
Field T, Perkins J, Tomblyn M, Hillgruber R, Nishihori T, Mishra A, Pidala J, Ayala E, Locke FL, Alsina M, Betts BC, Padron E, Fernandez HF, Lancet JE, List A, et al. Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine Blood. 122: 2152-2152. DOI: 10.1182/Blood.V122.21.2152.2152 |
0.496 |
|
| 2013 |
Pidala J, Sagatys EM, Lloyd M, Kim J, Yue B, Betts BC, Anasetti C. Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy Blood. 122: 2054-2054. DOI: 10.1182/Blood.V122.21.2054.2054 |
0.375 |
|
| 2013 |
Wood WA, Chai X, Weisdorf DJ, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer J, Arora M, Arai S, Jagasia MH, Storer B, Lee SJ, et al. Association of Comorbidity Scoring with Outcome in Patients with Chronic Graft Versus Host Disease Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.521 |
0.451 |
|
| 2013 |
Pidala J, Chai X, Martin PJ, Inamoto Y, Flowers MED, Cutler C, Palmer J, Weisdorf DJ, Pavletic SZ, Arora M, Arai S, Lee SJ. Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium Biology of Blood and Marrow Transplantation. 19: 967. DOI: 10.1016/J.Bbmt.2012.11.516 |
0.442 |
|
| 2013 |
Perez LE, Fernandez H, Tomblyn M, Locke F, Field T, Pidala J, Elmer E, Beato F, Anasetti C. A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients with Acute Graft Versus Host Disease Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.515 |
0.397 |
|
| 2013 |
Palmer J, Chai X, Martin PJ, Kurland BF, Pavletic SZ, Inamoto Y, Arora M, Cutler C, Weisdorf DJ, Flowers ME, Jagasia MH, Arai S, Pidala J, Lee SJ. Pulmonary Symptoms Measured by the NIH Lung Score Predict Overall Survival and Non-Relapse Mortality in Chronic GVHD Biology of Blood and Marrow Transplantation. 19: S336-S337. DOI: 10.1016/J.Bbmt.2012.11.514 |
0.324 |
|
| 2013 |
Perkins J, Field T, Locke F, Kharfan-Dabaja M, Ayala E, Tomblyn M, Pidala J, Nishihori T, Anasetti C. Assessment of a Disease Risk Index in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Fludarabine and Pharmacokinetically Dose-Targeted Intravenous Busulfan: Effect On Overall and Progression-Free Survival Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.444 |
0.497 |
|
| 2013 |
Kunter GM, Perkins J, Nishihori T, Locke F, Field T, Pidala J, Perez L, Kharfan-Dabaja M, Anasetti C, Fernandez H. Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.430 |
0.485 |
|
| 2013 |
Jim H, Quinn G, Barata-Bardiella A, Cases M, Cessna J, Christie J, Gonzalez L, Gwede C, Koskan A, Pidala J. Quality of Life Following Allogeneic Hematopoietic Cell Transplant: What Patients Wish They Had Known Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.249 |
0.472 |
|
| 2013 |
Jim H, Barata-Bardiella A, Small B, Jacobsen P, Anasetti C, Pidala J. Quality of Life in Patients Treated with Sirolimus and Tacrolimus for Prevention of Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 19: S151-S152. DOI: 10.1016/J.Bbmt.2012.11.106 |
0.419 |
|
| 2013 |
Pidala J, Locke FL, Anasetti C. Graft-versus-Host disease and Graft-versus-Tumor response Wintrobe's Clinical Hematology: Thirteenth Edition. 2206-2220. |
0.3 |
|
| 2012 |
Jim HS, Boyd TD, Booth-Jones M, Pidala J, Potter H. Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain Disorders & Therapy. 1. PMID 22905341 DOI: 10.4172/2168-975X.1000101 |
0.381 |
|
| 2012 |
Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, ... ... Pidala J, et al. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 1776-84. PMID 22863842 DOI: 10.1016/J.Bbmt.2012.06.018 |
0.505 |
|
| 2012 |
Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 120: 2545-52; quiz 2774. PMID 22773386 DOI: 10.1182/Blood-2012-04-424135 |
0.346 |
|
| 2012 |
Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Schultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 1649-55. PMID 22691695 DOI: 10.1016/J.Bbmt.2012.05.005 |
0.364 |
|
| 2012 |
Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 97: 1882-9. PMID 22689677 DOI: 10.3324/Haematol.2012.067140 |
0.49 |
|
| 2012 |
Inamoto Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, Cutler C, Pavletic SZ, Arora M, Jacobsohn D, Carpenter PA, Flowers ME, Khera N, Vogelsang GB, Weisdorf D, et al. Clinical benefit of response in chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 1517-24. PMID 22683612 DOI: 10.1016/J.Bbmt.2012.05.016 |
0.449 |
|
| 2012 |
Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: A Markov decision analysis Bone Marrow Transplantation. 47: 1164-1170. PMID 22562081 DOI: 10.1038/Bmt.2012.71 |
0.447 |
|
| 2012 |
Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, et al. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology. 157: 553-63. PMID 22449149 DOI: 10.1111/J.1365-2141.2012.09099.X |
0.422 |
|
| 2012 |
Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, ... ... Pidala J, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 119: 4083-90. PMID 22408257 DOI: 10.1182/Blood-2012-02-409763 |
0.485 |
|
| 2012 |
Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 119: 487-93. PMID 22153706 DOI: 10.1016/J.Ophtha.2011.08.040 |
0.465 |
|
| 2012 |
Jim HS, Small B, Hartman S, Franzen J, Millay S, Phillips K, Jacobsen PB, Booth-Jones M, Pidala J. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer. 118: 3407-16. PMID 22139882 DOI: 10.1002/Cncr.26645 |
0.406 |
|
| 2012 |
Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, Weisdorf DJ, Jagasia M, Cutler C, Palmer J, Jacobsohn D, Arai S, Lee SJ. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 97: 451-8. PMID 22058206 DOI: 10.3324/Haematol.2011.055186 |
0.513 |
|
| 2012 |
Pidala J, Perez L, Beato F, Anasetti C. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD Bone Marrow Transplantation. 47: 747-748. PMID 21874061 DOI: 10.1038/Bmt.2011.172 |
0.34 |
|
| 2012 |
Pidala J, Wang T, Haagenson MD, Spellman S, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, et al. Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes Blood. 120: 467-467. DOI: 10.1182/Blood.V120.21.467.467 |
0.515 |
|
| 2012 |
Inamoto Y, Chai X, Kurland B, Weisdorf DJ, Martin PJ, Jacobsohn D, Pidala J, Palmer J, Arai S, Cutler C, Jagasia M, Flowers ME, Arora M, Pavletic SZ, Vogelsang GB, et al. Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium Blood. 120: 464-464. DOI: 10.1182/Blood.V120.21.464.464 |
0.332 |
|
| 2012 |
Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey T, Jacobsen N, Kroeger N, Walker I, Territo MC, Light S, Laport GG, Nademanee A, Powles R, Keating A, et al. The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation Blood. 120: 4195-4195. DOI: 10.1182/Blood.V120.21.4195.4195 |
0.427 |
|
| 2012 |
Kharfan-Dabaja MA, Mhaskar R, Reljic T, Pidala J, Perkins J, Djulbegovic B, Kumar A. Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies Blood. 120: 4168-4168. DOI: 10.1182/Blood.V120.21.4168.4168 |
0.458 |
|
| 2012 |
Pidala J, Chai X, Kurland B, Arora M, Cutler C, Flowers ME, Inamoto Y, Jagasia M, Khera N, Palmer J, Vogelsang G, Lee SJ. Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium Blood. 120: 1940-1940. DOI: 10.1182/Blood.V120.21.1940.1940 |
0.474 |
|
| 2012 |
Veerapathran A, Pidala J, Beato F, Janssen WE, Yu X, Anasetti C. Tregs Specific for Minor Histocompatibility Antigens Blood. 120: 1891-1891. DOI: 10.1182/Blood.V120.21.1891.1891 |
0.382 |
|
| 2012 |
Pidala J, Kim J, Schell M, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez H, Field T, Locke F, Nishihori T, Ochoa J, Perez L, et al. Effectiveness of Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Results of a Donor Vs. No Donor Analysis Biology of Blood and Marrow Transplantation. 18: S267-S268. DOI: 10.1016/J.Bbmt.2011.12.528 |
0.514 |
|
| 2012 |
Nishihori T, Pidala J, Kim J, Tomblyn M, Anasetti C. Comparison of Sirolimus and Mycophenolate Mofetil as Salvage Treatment for Acute Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 18: S368. DOI: 10.1016/J.Bbmt.2011.12.439 |
0.446 |
|
| 2012 |
Treister N, Lee S, Chai X, Kurland B, Pidala J, Palmer J, Flowers M, Jagasia M, Pavletic S, Cutler C. Measurement of Oral Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 18: S363. DOI: 10.1016/J.Bbmt.2011.12.423 |
0.417 |
|
| 2012 |
Kharfan-Dabaja M, Mhaskar R, Pidala J, Perkins J, Djulbegovic B, Kumar A. Comparison of Mycophenolate Mofetil (MMF) Versus Methotrexate (MTX) for Prevention of Acute Graft-Versus-Host Disease: Results of a Meta-Analysis Biology of Blood and Marrow Transplantation. 18: S358-S359. DOI: 10.1016/J.Bbmt.2011.12.411 |
0.359 |
|
| 2012 |
CruzChacon A, Perkins J, Pidala J, Kim J, Yue B, Field T, Anasetti C. Impact of a Lower Busulfan Area Under the Concentration-Time Curve (AUC) Dosing Target on Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Biology of Blood and Marrow Transplantation. 18: S340. DOI: 10.1016/J.BBMT.2011.12.358 |
0.325 |
|
| 2012 |
Nishihori T, Ochoa-Bayona J, Pidala J, Shain K, Sullivan D, Baz R, Anasetti C, Alsina M. Allogeneic Hematopoietic Cell Transplantation for Consolidation of Vgpr or Cr in Myeloma Biology of Blood and Marrow Transplantation. 18: S298. DOI: 10.1016/J.Bbmt.2011.12.242 |
0.484 |
|
| 2012 |
Nishihori T, Ochoa-Bayona JL, Pidala J, Shain K, Baz R, Simonelli CM, Sullivan D, Anasetti C, Alsina M. A Phase 2 Study of Bortezomib Plus High-Dose Melphalan Conditioning for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.241 |
0.455 |
|
| 2012 |
Figueroa J, Perkins J, Anassetti C, Tomblyn M, Field T, Fernandez H, Ochoa J, Perez L, Alsina M, Locke F, Nishihori T, Pidala J, Ayala E. Myeloablative Doses of Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation in Non-Hodgkin'S Lymphoma Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.240 |
0.447 |
|
| 2012 |
Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, Weisdorf D, Jagasia M, Cutler C, Palmer J, Jacobsohn D, Arai S, Lee SJ. Overlap Subtype of Chronic GVHD Is Associated with Adverse Prognosis, Functional Impairment, and Inferior Patient Reported Outcomes: A Chronic GVHD Consortium Study Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.005 |
0.374 |
|
| 2011 |
Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control : Journal of the Moffitt Cancer Center. 18: 268-76. PMID 21976245 DOI: 10.1177/107327481101800407 |
0.529 |
|
| 2011 |
Pidala J. Progress in hematopoietic cell transplantation. Cancer Control : Journal of the Moffitt Cancer Center. 18: 212-3. PMID 21976239 DOI: 10.1177/107327481101800401 |
0.508 |
|
| 2011 |
Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. The Cochrane Database of Systematic Reviews. CD008818. PMID 21975786 DOI: 10.1002/14651858.Cd008818.Pub2 |
0.538 |
|
| 2011 |
Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 118: 5671-80. PMID 21948174 DOI: 10.1182/Blood-2011-02-337097 |
0.305 |
|
| 2011 |
Perez L, Anasetti C, Pidala J. Have we improved in preventing and treating acute graft-versus-host disease? Current Opinion in Hematology. 18: 408-13. PMID 21912253 DOI: 10.1097/Moh.0B013E32834B6196 |
0.54 |
|
| 2011 |
Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 96: 1678-84. PMID 21791465 DOI: 10.3324/Haematol.2011.049841 |
0.542 |
|
| 2011 |
Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 118: 4242-9. PMID 21791424 DOI: 10.1182/Blood-2011-03-344390 |
0.447 |
|
| 2011 |
Pidala J, Kurland BF, Chai X, Vogelsang G, Weisdorf DJ, Pavletic S, Cutler C, Majhail N, Lee SJ. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica. 96: 1528-35. PMID 21685473 DOI: 10.3324/Haematol.2011.046367 |
0.489 |
|
| 2011 |
Singh H, Werner LL, Asali S, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. American Journal of Hematology. 86: 625-7. PMID 21681787 DOI: 10.1002/Ajh.22041 |
0.403 |
|
| 2011 |
Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 96: 1351-6. PMID 21565902 DOI: 10.3324/Haematol.2011.041236 |
0.506 |
|
| 2011 |
Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1528-36. PMID 21440079 DOI: 10.1016/J.Bbmt.2011.03.006 |
0.487 |
|
| 2011 |
Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1505-11. PMID 21385623 DOI: 10.1016/J.Bbmt.2011.02.011 |
0.545 |
|
| 2011 |
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 117: 4651-7. PMID 21355084 DOI: 10.1182/Blood-2010-11-319509 |
0.438 |
|
| 2011 |
Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. International Journal of Hematology. 93: 206-12. PMID 21246311 DOI: 10.1007/S12185-010-0747-X |
0.5 |
|
| 2011 |
Pidala J, Khalil F, Fernandez H. Pulmonary alveolar proteinosis following allogeneic hematopoietic cell transplantation Bone Marrow Transplantation. 46: 1480-1483. PMID 21217786 DOI: 10.1038/Bmt.2010.321 |
0.474 |
|
| 2011 |
Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1237-44. PMID 21215811 DOI: 10.1016/J.Bbmt.2010.12.705 |
0.504 |
|
| 2011 |
Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity Bone Marrow Transplantation. 46: 641-649. PMID 20711242 DOI: 10.1038/Bmt.2010.190 |
0.375 |
|
| 2011 |
Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 239-48. PMID 20637884 DOI: 10.1016/J.Bbmt.2010.07.005 |
0.458 |
|
| 2011 |
Kunter GM, Perkins J, Perez L, Pidala J, Field T, Tomblyn M, Fernandez HF, Anasetti C. Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission Blood. 118: 891-891. DOI: 10.1182/Blood.V118.21.891.891 |
0.489 |
|
| 2011 |
Nishihori T, Ochoa-Bayona JL, Pidala J, Shain KH, Sullivan D, Baz R, Anasetti C, Alsina M. Allogeneic Hematopoietic Cell Transplantation for Consolidation of VGPR or CR In Myeloma Blood. 118: 4581-4581. DOI: 10.1182/Blood.V118.21.4581.4581 |
0.528 |
|
| 2011 |
Nishihori T, Pidala J, Kim J, Tomblyn M, Anasetti C. Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease Blood. 118: 4548-4548. DOI: 10.1182/Blood.V118.21.4548.4548 |
0.499 |
|
| 2011 |
Nishihori T, Ochoa L, Pidala J, Shain KH, Baz R, Simonelli C, Sullivan D, Anasetti C, Alsina M. A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma, Blood. 118: 4158-4158. DOI: 10.1182/Blood.V118.21.4158.4158 |
0.493 |
|
| 2011 |
Pidala J, Kim J, Jim H, Fernandez HF, Tomblyn M, Kharfan-Dabaja MA, Betts BC, Nishihori T, Xu M, Janssen WE, Locke FL, Ayala E, Perez L, Perkins J, Field T, et al. Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd Blood. 118: 323-323. DOI: 10.1182/Blood.V118.21.323.323 |
0.521 |
|
| 2011 |
Kharfan-Dabaja MA, Anasetti C, Luis N, Brand L, Perkins J, Fernandez HF, Ochoa-Bayona JL, Nishihori T, Perez LE, Ayala E, Pinilla-Ibarz J, Sokol L, Pidala J, Locke FL, Sotomayor EM, et al. Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression Blood. 118: 3022-3022. DOI: 10.1182/Blood.V118.21.3022.3022 |
0.409 |
|
| 2011 |
Inamoto Y, Cutler CS, Chai X, Arora M, Martin PJ, Pidala J, Palmer J, Pavletic SZ, Jagasia MH, Jacobsohn D, Carpenter PA, Flowers MED, Khera N, Vogelsang GB, Weisdorf DJ, et al. Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium Blood. 118: 1988-1988. DOI: 10.1182/Blood.V118.21.1988.1988 |
0.409 |
|
| 2011 |
Palmer J, Lee SJ, Chai X, Storer B, Pidala J, Cutler CS, Arora M, Flowers MED, Pavletic SZ, Vogelsang GB, Inamoto Y, Jagasia M, George C, Martin PJ. Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response Blood. 118: 1978-1978. DOI: 10.1182/Blood.V118.21.1978.1978 |
0.322 |
|
| 2011 |
Jacobsohn D, Lee SJ, Kurland B, Cutler CS, Pidala J, Carpenter PA, Chai S, Arai S, Arora M, Palmer J, Martin PJ, Pavletic SZ, Flowers ME. Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium Blood. 118: 151-151. DOI: 10.1182/Blood.V118.21.151.151 |
0.342 |
|
| 2011 |
Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jädersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, et al. A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS Blood. 118: 115-115. DOI: 10.1182/Blood.V118.21.115.115 |
0.55 |
|
| 2011 |
McClune B, Pedersen TL, Ahn KW, Warlick ED, Pidala J, Waller EK, Rizzo JD, Cairo MS, Woolfrey A, Artz A, Lazarus HM, Weisdorf DJ. Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years Blood. 118: 1015-1015. DOI: 10.1182/Blood.V118.21.1015.1015 |
0.506 |
|
| 2011 |
Pidala J, Tomblyn M, Nishihori T, Perkins J, Field T, Ayala E, Bookout R, Conwell M, Perez L, Ochoa L, Alsina M, Shapiro J, Tate C, Locke F, Fernandez H, et al. ATG for the Prevention of Severe Acute Graft-Versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.555 |
0.552 |
|
| 2011 |
Pidala J, Tomblyn M, Nishihori T, Perkins J, Field T, Ayala E, Alsina M, Ochoa L, Locke F, Perez L, Fernandez H, Anasetti C. Sirolimus Induces Complete Remission of Acute Graft-Versus-Host Disease Without Systemic Glucocorticoids Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.534 |
0.436 |
|
| 2011 |
Field T, Perkins J, Pidala J, Nishihori T, Tomblyn M, Fernandez H, Perez L, Karfan-Dabaja M, Komrokji R, Lancet J, Ayala E, Alsina M, Ochoa L, Kim J, List A, et al. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML Biology of Blood and Marrow Transplantation. 17: S312. DOI: 10.1016/J.Bbmt.2010.12.473 |
0.498 |
|
| 2011 |
Field T, Perkins J, Nishihori T, Pidala J, Tomblyn M, Fernandez H, Perez L, Kharfan-Dabaja M, Komrokji R, Lancet J, Ayala E, Alsina M, Ochoa L, Kim J, List A, et al. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Comparison of Survival in Patients With an Available Donor Compared to Patients Without a Donor in Patients Up to Age 75 Biology of Blood and Marrow Transplantation. 17: S300. DOI: 10.1016/J.Bbmt.2010.12.439 |
0.526 |
|
| 2011 |
Majhail NS, Quinn G, Brzauskas R, Wang Z, Chow E, Gilleece M, Halter J, Joshi S, Pidala J, Bolwell B, Jacobsohn D, Socie G, Sorror M, Wingard JR, Rizzo JD, et al. Transplant Physician Perceptions and Practice Patterns Regarding Fertility Preservation in Hematopoietic-Cell Transplant (HCT) Recipients Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.263 |
0.474 |
|
| 2011 |
Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in Management of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation: Results of a National Survey of Asbmt Transplant Physicians Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.261 |
0.473 |
|
| 2011 |
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf D, Pavletic S, Cutler C, Arai S, Jagasia M, Palmer J, Lee S. Chronic GVHD Severity and Sensitivity to Change in Patient-Reported Quality of Life: Results From the Chronic GVHD Consortium Biology of Blood and Marrow Transplantation. 17: S238. DOI: 10.1016/J.Bbmt.2010.12.257 |
0.359 |
|
| 2011 |
Nishihori T, Alekshun T, Sullivan D, Kharfan-Dabaja M, Raychaudhuri J, Ochoa-Bayona J, Shain K, Yarde D, Oliviera V, Pidala J, Fulp W, Chen D, Kim J, Simonelli C, Maddox B, et al. Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia Biology of Blood and Marrow Transplantation. 17: S200-S201. DOI: 10.1016/J.Bbmt.2010.12.150 |
0.456 |
|
| 2011 |
Pidala J, Anasetti C. Advances in Allogeneic Hematopoietic Cell Transplantation: Progress in Transplantation Technology and Disease-Specific Outcomes Advances in Malignant Hematology. 367-383. DOI: 10.1002/9781444394016.ch23 |
0.443 |
|
| 2010 |
Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Annals of Transplantation. 15: 21-9. PMID 21183872 |
0.419 |
|
| 2010 |
Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. Journal of Hematology & Oncology. 3: 36. PMID 20925957 DOI: 10.1186/1756-8722-3-36 |
0.458 |
|
| 2010 |
Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. American Journal of Hematology. 85: 904-7. PMID 20890908 DOI: 10.1002/Ajh.21851 |
0.57 |
|
| 2010 |
Kharfan-Dabaja MA, Pidala J, Anasetti C. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. Blood. 115: 4316-7; author reply. PMID 20508174 DOI: 10.1182/Blood-2010-01-265728 |
0.51 |
|
| 2010 |
Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 1504-18. PMID 20096359 DOI: 10.1016/J.Bbmt.2010.01.007 |
0.479 |
|
| 2010 |
Pidala J, Anasetti C. Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse? Haematologica. 95: 660-5. PMID 20015881 DOI: 10.3324/Haematol.2009.015818 |
0.526 |
|
| 2010 |
Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease Bone Marrow Transplantation. 45: 1347-1351. PMID 19966849 DOI: 10.1038/Bmt.2009.343 |
0.472 |
|
| 2010 |
Pidala J, Bloom GC, Enkemann S, Eschrich S, Lancaster J, Anasetti C. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 729-38. PMID 19922809 DOI: 10.1016/J.Bbmt.2009.11.009 |
0.519 |
|
| 2010 |
Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. British Journal of Haematology. 148: 373-85. PMID 19919651 DOI: 10.1111/J.1365-2141.2009.07992.X |
0.413 |
|
| 2010 |
Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease Bone Marrow Transplantation. 45: 919-924. PMID 19767783 DOI: 10.1038/Bmt.2009.252 |
0.461 |
|
| 2010 |
Pidala J, Kurland B, Chai S, Majhail NS, Weisdorf DJ, Cutler C, Jagasia M, Palmer J, Arora M, Martin PJ, Jacobsohn D, Vogelsang GB, Pavletic SZ, Lee SJ. Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium Blood. 116: 393-393. DOI: 10.1182/Blood.V116.21.393.393 |
0.435 |
|
| 2010 |
Veerapathran A, Pidala J, Beato F, Yu X, Anasetti C. High Frequency of Alloantigen-Specific Regulatory T-Cells In Human Blood Allow Rapid Ex Vivo Expansion for Adoptive Therapy. Blood. 116: 3747-3747. DOI: 10.1182/Blood.V116.21.3747.3747 |
0.337 |
|
| 2010 |
Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja MA, Kumar A. Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis Blood. 116: 3511-3511. DOI: 10.1182/Blood.V116.21.3511.3511 |
0.509 |
|
| 2010 |
Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, Lancet JE, Komrokji RS, ochoa-Bayona J, Alsina M, Ayala E, Kim J, List AF, et al. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor Blood. 116: 2381-2381. DOI: 10.1182/Blood.V116.21.2381.2381 |
0.544 |
|
| 2010 |
Arai S, Jagasia M, Arora M, Miklos D, Chai X, Storer B, Martin PJ, Cutler C, Weisdorf DJ, Pidala J, Palmer J, Flowers M, Jacobsohn D, Carpenter PA, Pavletic SZ, et al. Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium Blood. 116: 220-220. DOI: 10.1182/Blood.V116.21.220.220 |
0.434 |
|
| 2010 |
Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, Komrokji RS, Lancet JE, Kim J, Ayala E, Alsina M, ochoa-Bayona J, List AF, et al. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML Blood. 116: 1333-1333. DOI: 10.1182/Blood.V116.21.1333.1333 |
0.566 |
|
| 2010 |
Nishihori T, Perkins J, Pidala J, Roman J, Kim J, Fernandez H, Anasetti C, Kharfan-Dabaja M. Allogeneic Hematopoietic Stem Cell Transplantation In Myelofibrosis: Single Center Experience Biology of Blood and Marrow Transplantation. 16: S293. DOI: 10.1016/J.Bbmt.2009.12.410 |
0.448 |
|
| 2010 |
Roman-Diaz JL, Pidala J, Nishihori T, Perkins J, Tate C, Ochoa J, Ayala E, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Targeted Iv Busulfan And Fludarabine Followed By Post-Allogeneic Hematopoietic Cell Transplantation Rituximab Demonstrate Encouraging Activity In High Risk CD20+Positive Lymphoid Malignancies Without Increased Infectious Complications Biology of Blood and Marrow Transplantation. 16. DOI: 10.1016/J.Bbmt.2009.12.400 |
0.455 |
|
| 2009 |
Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 1415-21. PMID 19822301 DOI: 10.1016/J.Bbmt.2009.07.009 |
0.525 |
|
| 2009 |
Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 1116-21. PMID 19660725 DOI: 10.1016/J.Bbmt.2009.05.019 |
0.441 |
|
| 2009 |
Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 881-5. PMID 19539221 DOI: 10.1016/J.Bbmt.2009.03.020 |
0.56 |
|
| 2009 |
Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 114: 7-19. PMID 19336756 DOI: 10.1182/Blood-2008-10-182592 |
0.477 |
|
| 2009 |
Pidala JA, Kim J, Anasetti C, Alsina M, Ayala E, Field T, Kharfan-Dabaja MA, Ochoa JL, Perez L, Perkins J, Tomblyn M, Fernandez HF. Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia. Blood. 114: 2290-2290. DOI: 10.1182/blood.v114.22.2290.2290 |
0.409 |
|
| 2009 |
Pidala JA, Hoda D, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene JN, Janssen WE, Fernandez HF, et al. Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease. Blood. 114: 2235-2235. DOI: 10.1182/blood.V114.22.2235.2235 |
0.426 |
|
| Show low-probability matches. |